VECTURA GROUP PLC

Description

Vectura Group plc is a UK-based global pharmaceutical company. It is involved in the development of inhaled medicines and therapies to fight respiratory diseases, like asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Its services include pharmaceutical analysis, formulation development, devise platform selection, process development and technical transfer, product manufacturing and regulatory services. It was founded in the year 1997 and its headquarters are situated in Chippenham, Wiltshire. It is listed on the London Stock Exchange publicly and it falls under the FTSE 250 index. Vectura Group plc has many subsidiaries, which include Vectura GmbH, Vectura Group Services Limited, Vectura Delivery Devices Limited, and Vectura Limited etc. The company offers 13 inhaled on-market medicines, which are launched by its partners and licensees. These partners have successfully brought DPI, pMDI and nebulizer medicines in the market with the help and support of Vectura Group. As per the 2020 data, around 10 million patients have been using products based on Vectura’s intellectual property.

The company invests in research and development of therapeutic medicines and in their commercialisation. It produces all types of inhaler medications, including LABA (Long-acting Beta-agnostics), LAMA (Long-acting muscarinic antagonists), and ICS (Inhaled corticosteroids). Some products in these inhaler categories include Ultibro Breezhaler, Seebri Breezhaler, AirFluSal Forspiro, Incruse Ellipta etc. It also produces dry powder inhalers, like Unit Dose dry powder inhaler, GyroHaler, Lever-operated, and Open-inhale-close. Apart from inhalers, it also offers smart nebulizer delivery systems, which are of great significance in targeted drug delivery to the lungs. FOX and AKITA JET are a part of this smart nebulizer delivery system.

The goal of the company is to use science and technology and develop high quality medicines through sustainable business solutions. It aims to maximize the risk-adjusted returns for all stakeholders, including patients, partners, suppliers, customers and shareholders, and create long-term value for the business as well as the wider community. It promotes a culture of transparency and accountability and works in alignment with an ethical code of conducting business. It has a comprehensive ESG framework in place and focuses on all its environmental, social as well as corporate responsibilities.

It tries to reduce its energy usage and carbon footprint through sustainable practices like recycling. The company focuses on being a good corporate citizen and works towards the wellbeing of employees, and promoting diversity and inclusion. It has received an MSCI ESG Rating of ‘A’ considers its commitments towards enacting the ESG principles.